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ABSTRACT
Echistatin, a cyclic RGD peptide, which is an antagonist of avβ3 integrin 
(disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane 
(CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic 
model. A high-metastatic variant of human osteosarcoma, 143B-LM4, overexpressing 
avβ3 integrin was used. Tumor angiogenesis by high-metastatic variant 143B-LM4 
cells in the CAM was significantly inhibited by echistatin (P<0.05) as was overall 
growth. A doxorubicin (DOX)-echistatin combination inhibited orthotopic tumor 
growth compared to untreated control (P<0.01) or DOX alone (P<0.05) in nude mice. 
Tumor-bearing mice treated with the DOX-echistatin combination survived longer 
than those treated with DOX alone or control PBS (P<0.01 and P<0.01, respectively). 
Echistatin also inhibited experimental lung metastasis of 143B-LM4 cells in nude mice. 
These results suggest that DOX in combination with a disintegrin has potential to treat 
osteosarcoma and that avβ3 integrin may be a target for osteosarcoma.
INTRODUCTION
Osteosarcoma is a highly-metastatic cancer that 
is often fatal after failure of first-line chemotherapy [1]. 
Integrins are thought to play a major role in metastasis in 
this disease [2].
A high metastatic variant of 143B osteosarcoma 
cells (143B-LM4) was isolated in our laboratory by serial 
orthotopic passage and was found to overexpress αvβ3 
integrin, compared to parental cells [2].
We therefore decided to target αvβ3 integrin as a 
potential improved therapy for osteosarcoma. Using the 
143B-LM4 human osteosarcoma cell line, expressing RFP 
in the cytoplasm and GFP in the nucleus (143B-LM4-
GEP-REP) (Figure 1), single cancer-cell seeding in the 
lung after i.v. injection in real time of osteosarcoma cells 
was imaged. Lung seeding by 143B-LM4 was greatly 
inhibited by the anti-β1 integrin monoclonal antibody, 
AIIB2. AIIB2 also significantly inhibited spontaneous 
lung metastasis and increased survival of mice with 
orthotopically-growing143B-RFP [2].
The in vitro efficacy of the disintegrin echistatin was 
tested on the 143B-LM4 high-metastatic variant, which 
over-expresses αvβ3 integrin. Echistatin is an RGD cyclic 
peptide and an antagonist of αvβ3 integrin. Echistatin 
inhibited cell proliferation, migration, invasion, and 
adhesion of 143B-LM4 cells. 143B-LM4 cell proliferation 
decreased after treatment with echistatin in a time-
dependent and dose-dependent manner. In vitro migration 
and invasion as well as cell adhesion to vitonectin-coated 
dishes of 143B-LM4 cells were also inhibited by echistatin 
in a dose-dependent manner [3].
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In the present study, we evaluated echistatin, 
targeting in combination with doxorubicin [4], against the 
143B-LM4 cell line, in the chick embryo and in orthotopic 
and experimental-metastasis nude-mouse models.
RESULTS AND DISCUSSION
Efficacy of echistatin on the 143B-LM4 in the 
chick embryo
Angiogenesis was initiated with fragments of 
the 143B-LM4 tumor implanted on the chorioallantoic 
membrane (CAM). After 24 hr, the embryos received a 
single inoculation of the echistatin or control PBS. Forty-
eight hr after echistatin administration, tumor-induced 
angiogenesis by 143B-LM4 cells in the CAM was 
significantly inhibited by echistatin (P < 0.05) (Figure 2A, 
2B). Tumor regression was also observed after treatment 
with echistatin compared to control PBS (Figure 2A, 2B).
Efficacy of DOX-echistatin combination against 
143B-LM4 in nude mice
The efficacy of a DOX-echistatin combination 
in the orthotopic 143B-LM4 tumor model in nude mice 
was determined. 143B-LM4 cells were transplanted in 
the tibia of 15 nude mice, and they were allowed to grow 
to palpable size. Mice were divided into three groups 
(5 mice PBS, 5 mice DOX, and 5 mice DOX-echistatin 
combination). Tumors were treated with intravenous 
injections of DOX (5 μg); DOX (5 μg) echistatin (4 μg); 
or PBS (100 μl) at one-week intervals. Four weeks after 
implantation of 143B-LM4 cells, the average primary 
tumor volume in the DOX-echistatin combination group 
was significantly smaller than that of the untreated control 
(P < 0.01) and that of the DOX-only (P <0.05) (Figure 
3A & 3B). No adverse effects of DOX, DOX-echistatin 
combination, or PBS intravenous injection, such as body 
weight loss, were observed. Tumor-bearing mice treated 
with the DOX-echistatin combination survived longer than 
those treated with DOX alone or control PBS (P<0.01 and 
P<0.01, respectively) (Figure 3C). By day 35, all PBS 
control mice had to be euthanized. By 42 days, all mice 
treated with DOX were also euthanized due to tumor size. 
Two mice treated with the DOX-echistatin combination 
were euthanized by days 44 and 57, respectively. The 
remaining three mice treated with DOX-echistatin 
combination were alive up to three months from the time 
of tumor transplantation. No significant mouse body 
weight loss was observed in the treated groups compared 
to the control.
Echistatin decreases 143B-LM4 osteosarcoma 
experimental lung metastases in nude mice
To determine whether echistatin could inhibit 
osteosarcoma experimental lung metastases, 143B-LM4 
cells pretreated with echistatin were injected into the tail veil 
of nude mice. Untreated mice were used as the control. In 
another group on the following day, the mice were treated 
Figure 1: Dual-color 143B-LM4 human osteosarcoma cells expressing GFP in the nucleus and RFP in the cytoplasm 
in vitro. The FV1000 confocal microscope (Olympus, Tokyo, Japan) was used to obtain images (20X).
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Figure 3: Efficacy of echistatin in combination with DOX on the 143B-LM4 orthotopic model in nude mice. A. Efficacy 
of echistatin on metastasis in the 143B-LM4 orthotopic model in nude mice four weeks after transplantation in the tibia. The OV100 was 
used to obtain fluorescences images. Bar: 10 mm. B. Tumor volume four weeks after transplantation in the tibia. C. Kaplan-Meyer survival 
curves with the DOX-echistatin combination compared with control (PBS) or DOX-alone. P<0.01 for the DOX-echistatin combination on 
survival versus DOX- or PBS-treated animals.
Figure 2: Efficacy of echistatin on tumor-induced angiogenesis and tumor growth in the chick chorioallantoic membrane 
(CAM). A. 143B-LM4-GEP-REP tumor fragments which grew on the CAM for 7 days were resected and implanted on another CAM 
which was treated with echistatin. Angiogenesis of the 143B-LM4 tumor was inhibited by echistatin compared with control (PBS). Tumor 
regression was also observed after treatment with echistatin. Bar: 2 mm. B. Quantitation of vessels vascularizing the tumor. Echistatin 
significantly decreased vascularization of the 143B tumor on the CAM (P<0.05). The OV100 variable-magnification fluorescence imager 
(Olympus, Tokyo, Japan) was used to obtain images. Error bars indicated SD.
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intravenously with echistatin (0.1 mg/kg). Lung samples 
were harvested from all of the mice one week after 143B-
LM4 injection and imaged under fluorescence microscopy. 
The total number of metastases per lung was counted and 
averaged among the mice. Control mice had an average 
number of 105.8 pulmonary metastases. In contrast, mice 
treated with echistatin intravenously or in vitro had an 
average number of 25.3 or 10.2 experimental metastases, 
respectively (P < 0.01 and P < 0.01, respectively vs. 
untreated control) (Figure 4A & 4B).
Future studies will examine the cellular, histological 
and angiogenic effects of echistatin on both primary 
tumors and lung metastasis.
DOX is the one of the most frequently used drugs 
to treat osteosarcoma [5]. In the present study, there was 
a significant decrease in tumor size of a high-metastatic 
variant osteosarcoma, 143B-LM4 that overexpresses αvβ3 
integrin in mice treated with the combination of DOX and 
echistatin compared to DOX alone or untreated controls. 
These results suggest that DOX in combination with 
echistatin has clinical potential in osteosarcoma. Since 
echistatin is a disintegrin, the results of the present study 
suggest αvβ3 integrin may be a target in osteosarcoma.
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [6-11].
MATERIALS AND METHODS
Cell cultures and chemicals
143B-LM4 cells expressing GEP in the nucleus 
and REP in the cytoplasm (143B-LM4-GEP-REP) [12] 
(Figure 1) were maintained with RPMI 1640 median 
(Irvine Scientific, Santa Ana, CA) containing 15% fetal 
bovine serum (FBS) (Omega Scientific, San Diego, 
CA) and 1% penicillin/streptomycin at 37°C in 5% 
CO
2
. Echistatin was purchased from Tocris Bioscience 
(Ellisville, MO), diluted with distilled water, and stored 
at -20°C.
Angiogenesis on the chick chorioallantoic 
membrane
The chorioallantoic membrane (CAM) assay for 
tumor-induced angiogenesis was performed as previously 
described [13, 14]. Ten-day-old chick embryos were 
purchased from Mclntyre Poultry (Lakeside, CA) and 
were incubated at 37°C with 60% humidity. A small hole 
was made through the shell at the end of the egg directly 
over the air sac with the use of a small craft drill. A second 
hole was drilled on the broad side of the egg directly over 
embryonic blood vessels, as determined previously by 
candling. Negative pressure was applied to the original 
hole, which resulted in the CAM pulling away from the 
shell membrane and creating a false air sac. A 1.0 cm × 
1.0 cm square window was cut through the shell over the 
dropped CAM with the use of a small model grinding 
wheel to create a window that allowed direct access to the 
underlying CAM.
143B-LM4-GEP-REP cells were seeded on the 
CAMs of 10-day-old chick embryos. A cell suspension 
of 143B-LM4-GFP-RFP (1×108) was applied to the 
CAMs in a total volume of 30 μl RPMI 1640 medium 
with 15% FBS. The windows were sealed with tape, 
and the embryos were incubated for 7 days to allow 
growth of the human tumors. At the end of 7 days, the 
tumors were excised and trimmed free of surrounding 
Figure 4: Echistatin decreases the number of experimental lung metastases in 143B-LM4 cells. A. Fluorescence imaging of 
efficacy of echistatin on experimental metastasis of 143B-LM4-GFP-REP cells in nude mice one week after injection. The OV100 was used 
for fluorescence imaging. Bar: 2 mm. B. Quantitation of experimental lung metastases formed by 143B-LM4 cells. Echistatin decreased the 
number of experimental lung metastases in 143B-LM4 cells compared to untreated controls (P<0.01). Error bars indicate SD.
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CAM tissue. The tumors were then sliced into fragments 
of approximately 50 mg for use in the following 
angiogenesis assays.
Angiogenesis was induced in the chick embryo by 
implanting 50 mg fragments of 143B-LM4 tumor on the 
CAMs of 10-day-old embryos. After 24 h, echistatin (4 μg/
embryo) or control PBS were injected. At the end of the-
3-day incubation period, images were obtained with the 
OV100 Small Animal Imaging System (Olympus, Tokyo, 
Japan) and then angiogenesis was quantitated.
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. All 
mouse surgical procedures and imaging were performed 
with the animals anesthetized by subcutaneous injection 
of a ketamine mixture (0.02 ml solution of 20 mg/
kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate). The response of animals during 
surgery was monitored to ensure adequate depth of 
anesthesia. The animals were observed on a daily basis 
and humanely sacrificed by CO
2
 inhalation if they met the 
following humane endpoint criteria: severe tumor burden 
(more than 20 mm in diameter), prostration, significant 
body weight loss, difficulty breathing, rotational motion 
and body temperature drop. Animals were housed in a 
barrier facility on a high efficacy particulate arrestance 
(HEPA)-filtered rack under standard conditions of 12-
hour light/dark cycles. The animals were fed an autoclaved 
laboratory rodent diet. All animal studies were conducted 
in accordance with the principles and procedures outlined 
in the National Institutes of Health Guide for the Care and 
Use of Animals under Assurance Number A3873-1.
Nude mouse orthotopic metastatic model
143B-LM4 cells (5×105) were transplanted into 
the tibia of the nude mice under the ketamine anesthesia, 
described above,  as previously described [15]. One week 
after intra-tibial implantation, animals were separated 
into three groups and treated with doxorubicin (DOX) 
(0.25 mg/kg), a DOX (0.25 mg/kg)-echistatin (0.1 mg/
kg) combination, or control PBS in each group five times 
at 1-week intervals. Tumor size was measured every other 
day and the mean tumor volume was calculated by the 
formula (square root of width×length/0.52) [16]. Mice were 
euthanized when tumor volume became approximately 2.0 
cm3. 
The effect of echistatin on experimental lung 
metastases
To determine whether echistatin could inhibit 
experimental osteosarcoma pulmonary metastases, a 
total of 200 μl medium containing 143B-LM4 cells 
(1.5×106) were injected into the tail vein of nude mice. 
The following day, animals were separated into two 
groups and treated with echistatin (0.1 mg/kg) or control 
PBS intravenously. In another experiment, 143B-LM4 
cells treated with echistatin (1 μg/ml) prior to injection 
for 1 hr in vitro and then the cells were injected. One 
week after tumor injection, the lungs were harvested and 
imaged under fluorescence microscopy (OV100). The total 
number of metastases per lung was counted and averaged 
among the mice.
In vivo imaging
The OV100 small animal imaging system (Olympus 
Corp., Tokyo, Japan), was used. The OV100 contains 
an MT-20 light source (Olympus Biosystems, Planegg, 
Germany) and DP70 CCD camera (Olympus) for 
subcellular imaging in live mice. The optics of the OV100 
have been specially developed for macroimaging as well 
as microimaging with high light-gathering capacity. The 
instrument incorporates a unique combination of high 
numerical aperture and long working distance. Four 
individually optimized objective lenses, parcentered 
and parfocal, provide a 105-fold magnification range 
for seamless imaging of the entire body down to the 
subcellular level without disturbing the animal [17, 18].
Imaging was also performed with an FV 1000 laser-
scanning confocal microscope (Olympus, Tokyo, Japan) 
with a XLUMPLFL 20× (0.95 NA) water-immersion 
objective. GFP was excited at 488 nm. Images were 
produced with FV10-ASW Fluoview software (Olympus) 
and ImageJ and were not modified beyond the standard 
adjustment of intensity levels [19].
Statistical analysis
The data are presented as mean ± SD or mean ± 
SEM. Statistical analysis methods were the standard two-
tailed Student’s t-test for two data sets and ANOVA for 
multiple data sets. The animal survival data were analyzed 
using Kaplan-Meier survival analysis and log-rank test. P 
values of less than 0.05 were considered significant.
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